Literature DB >> 8688324

Prognostic significance of p53 overexpression and mutation in colorectal adenocarcinomas.

D R Smith1, C Y Ji, H S Goh.   

Abstract

The p53 tumour-suppressor gene is found altered in the majority of colorectal cancers. Lesions include allelic loss, mutation of the gene and overexpression of the p53 protein. All of these lesions have been analysed for prognostic significance, and whereas both mutation and allelic loss have been shown to be reasonably useful markers of prognosis, the utility of overexpression of the p53 protein is more ambiguous. Given that many authors use p53 overexpression as a marker for point mutation this issue is of some importance. We have therefore examined 100 colorectal carcinomas for mutation of the p53 gene, as well as overexpression of the p53 protein. Results show that whereas mutation of the p53 gene is associated with p53 overexpression, the degree of association depends, at least in part, upon the particular antibody used. Moreover, although mutation of the p53 gene does provide prognostic information, overexpression of the p53 protein, as detected with two antibodies, does not. These results suggest that immunohistochemistry is not a suitable alternative to direct detection of mutation in assessing prognosis in colorectal cancer patients.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8688324      PMCID: PMC2074579          DOI: 10.1038/bjc.1996.340

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


  60 in total

1.  Use of avidin-biotin-peroxidase complex (ABC) in immunoperoxidase techniques: a comparison between ABC and unlabeled antibody (PAP) procedures.

Authors:  S M Hsu; L Raine; H Fanger
Journal:  J Histochem Cytochem       Date:  1981-04       Impact factor: 2.479

2.  Adenovirus E1b-58kd tumor antigen and SV40 large tumor antigen are physically associated with the same 54 kd cellular protein in transformed cells.

Authors:  P Sarnow; Y S Ho; J Williams; A J Levine
Journal:  Cell       Date:  1982-02       Impact factor: 41.582

3.  Energy requirement for degradation of tumor-associated protein p53.

Authors:  R M Gronostajski; A L Goldberg; A B Pardee
Journal:  Mol Cell Biol       Date:  1984-03       Impact factor: 4.272

4.  Two distinct mechanisms regulate the levels of a cellular tumor antigen, p53.

Authors:  N C Reich; M Oren; A J Levine
Journal:  Mol Cell Biol       Date:  1983-12       Impact factor: 4.272

5.  Detection of T and B cell antigens hybridoma monoclonal antibodies: a biotin-avidin-horseradish peroxidase method.

Authors:  R Warnke; R Levy
Journal:  J Histochem Cytochem       Date:  1980-08       Impact factor: 2.479

6.  Cancer of the colon: the influence of the no-touch isolation technic on survival rates.

Authors:  R B Turnbull; K Kyle; F R Watson; J Spratt
Journal:  Ann Surg       Date:  1967-09       Impact factor: 12.969

7.  p53 gene mutations occur in combination with 17p allelic deletions as late events in colorectal tumorigenesis.

Authors:  S J Baker; A C Preisinger; J M Jessup; C Paraskeva; S Markowitz; J K Willson; S Hamilton; B Vogelstein
Journal:  Cancer Res       Date:  1990-12-01       Impact factor: 12.701

8.  Trends in right and left-sided colon cancer.

Authors:  R W Beart; L J Melton; M Maruta; M B Dockerty; H B Frydenberg; W M O'Fallon
Journal:  Dis Colon Rectum       Date:  1983-06       Impact factor: 4.585

9.  Cellular immortalization by a cDNA clone encoding the transformation-associated phosphoprotein p53.

Authors:  J R Jenkins; K Rudge; G A Currie
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

10.  Cooperation between gene encoding p53 tumour antigen and ras in cellular transformation.

Authors:  L F Parada; H Land; R A Weinberg; D Wolf; V Rotter
Journal:  Nature       Date:  1984 Dec 13-19       Impact factor: 49.962

View more
  13 in total

Review 1.  What we could do now: molecular pathology of colorectal cancer.

Authors:  R S Houlston
Journal:  Mol Pathol       Date:  2001-08

2.  Overexpression of TP53 protein is associated with the lack of adjuvant chemotherapy benefit in patients with stage III colorectal cancer.

Authors:  David S Williams; Dmitri Mouradov; Clare Browne; Michelle Palmieri; Meg J Elliott; Rebecca Nightingale; Catherine G Fang; Rita Li; John M Mariadason; Ian Faragher; Ian T Jones; Leonid Churilov; Niall C Tebbutt; Peter Gibbs; Oliver M Sieber
Journal:  Mod Pathol       Date:  2019-08-30       Impact factor: 7.842

Review 3.  Genetic prognostic markers in colorectal cancer.

Authors:  R S Houlston; I P Tomlinson
Journal:  Mol Pathol       Date:  1997-12

4.  p53 protein accumulation and p53 gene mutation in colorectal cancer.

Authors:  A Nasierowska-Guttmejer ; L Trzeciak ; M P Nowacki ; J Ostrowski
Journal:  Pathol Oncol Res       Date:  2000       Impact factor: 3.201

5.  Prognostic significance of p53-expression in colorectal carcinoma as measured by a luminometric immunoassay.

Authors:  Oliver Lotter; Amro Amr; Farouk Safi
Journal:  Ger Med Sci       Date:  2010-10-08

Review 6.  Molecular lesions in colorectal cancer: impact on prognosis? Original data and review of the literature.

Authors:  B Klump; O Nehls; T Okech; C-J Hsieh; V Gaco; F S Gittinger; M Sarbia; F Borchard; A Greschniok; H H Gruenagel; R Porschen; M Gregor
Journal:  Int J Colorectal Dis       Date:  2003-06-21       Impact factor: 2.571

7.  Relationship between VEGF and p53 expression and tumor cell proliferation in human gastrointestinal carcinomas.

Authors:  Elvira Montero; Carmen Abreu; Paola Tonino
Journal:  J Cancer Res Clin Oncol       Date:  2007-07-17       Impact factor: 4.553

8.  Prostate tumours from an Asian population: examination of bax, bcl-2, p53 and ras and identification of bax as a prognostic marker.

Authors:  S J Chia; W Y Tang; J Elnatan; W M Yap; H S Goh; D R Smith
Journal:  Br J Cancer       Date:  2000-09       Impact factor: 7.640

9.  Thymidilate synthase and p53 primary tumour expression as predictive factors for advanced colorectal cancer patients.

Authors:  A Paradiso; G Simone; S Petroni; B Leone; C Vallejo; J Lacava; A Romero; M Machiavelli; M De Lena; C J Allegra; P G Johnston
Journal:  Br J Cancer       Date:  2000-02       Impact factor: 7.640

10.  Increased serum p53 antibody levels indicate poor prognosis in patients with colorectal cancer.

Authors:  U Kressner; B Glimelius; R Bergström; L Påhlman; A Larsson; G Lindmark
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.